NCT03034356CompletedPhase 1/2

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

Source: ClinicalTrials.gov · Last updated 11 Aug 2026

Brief summary (registry, in English)

This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure drug, also called an anticonvulsant.

Status (registry): Completed
Phase (registry): Phase 1/2
Study type: Interventional
Enrollment: 67 (actual)
First submitted: 25 Jan 2017
Start date: 15 Aug 2018
Primary completion date: 30 Jun 2024
Lead sponsor: VA Office of Research and Development
Diseases: Schizophrenia
NCT number: NCT03034356

What you commit to

Study type: Interventional · Phase 1/2
Participants enrolled: 67
From 15 Aug 2018 to the primary completion date, 30 Jun 2024
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

Significant neurological disorders

Other

Substance abuse
Significant head trauma/injury
Pregnancy
MRI-specific exclusion criteria, e.g.,:
- claustrophobia
- weight\>400 lbs
- metal in the body

Who the study is looking for

Diagnosis of schizophrenia or schizoaffective disorder
Good general health
Normal vital signs (blood pressure, pulse, respiration)

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Rocky Mountain Regional VA Medical Center, Aurora, CO Coordinator of this site? Confirm its status	Aurora	United States	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.